Delma Caiati
Stock Analyst at Guggenheim
(n/a)
# 5,039
Out of 5,043 analysts
6
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Delma Caiati
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $80 | $37.22 | +114.94% | 1 | Oct 5, 2026 | |
| MPLT MapLight Therapeutics | Initiated Coverage: Hold | n/a | $8.83 | - | 1 | Oct 5, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $207 | $142.44 | +45.32% | 1 | Oct 5, 2026 | |
| OVID Ovid Therapeutics | Initiated Coverage: Buy | $7 | $2.46 | +184.55% | 1 | Oct 5, 2026 | |
| RAPP Rapport Therapeutics | Initiated Coverage: Buy | $65 | $30.65 | +112.07% | 1 | Oct 5, 2026 | |
| XENE Xenon Pharmaceuticals | Initiated Coverage: Buy | $73 | $36.44 | +100.33% | 1 | Oct 5, 2026 |
LB Pharmaceuticals
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $37.22
Upside: +114.94%
MapLight Therapeutics
Oct 5, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $8.83
Upside: -
Neurocrine Biosciences
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $207
Current: $142.44
Upside: +45.32%
Ovid Therapeutics
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.46
Upside: +184.55%
Rapport Therapeutics
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $65
Current: $30.65
Upside: +112.07%
Xenon Pharmaceuticals
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $73
Current: $36.44
Upside: +100.33%